In an exclusive interview, GSK’s Senior VP for Vaccines R&D Dr Emmanuel Hanon discusses how the sharing of GSK’s adjuvant technology with a wealth of scientific institutions and companies globally can contribute to the rapid development of a safe and effective COVID-19 vaccine. Dr Hanon outlines the challenges inherent in manufacturing potential vaccines at scale and bringing them to market, as well as where the vaccine industry stands today in terms of innovation and public perception.
We have several agreements in place ... We hope that this combined effort will lead to a number of successful COVID-vaccines that will use our adjuvant becoming available for people around the world at significant scale.
